Spiracur Inc., the developer of disposable, non-powered negative pressure wound therapy (NPWT) solutions, today announced the introduction of its ciSNaP Closed Incision System with its proprietary controlled tension relief for improved healing of high-risk surgical incisions.
The new device expands upon the company's innovative SNaP Wound Care System platform and increases its patient population to include those undergoing high-risk procedures such as orthopaedic, abdominal, vascular and podiatric surgeries. Offering a sterile post-operative negative pressure dressing, the ciSNaP System is applied over stapled or sutured incisions in the operating room and may be left on the wound for up to seven days. It is the only NPWT device to create a tension relief over a surgical wound by bringing the incision edges together for improved healing, and it may improve the aesthetic appearance of the incision.
"I use the new ciSNaP on my higher-risk surgeries because it provides extra protection and stability to the incision," said Christopher Bellicini, D.O., Excela Health Orthopedics and Sports Medicine in Greensburg, Penn. "In my experience, the new device produces excellent results by completely eliminating the need for daily non-sterile dressing changes during the patient's hospital stay and instead, promoting successful healing of these high-risk wounds. As a result, the threat of infection and the possibility of dehiscence (wound re-opening along incision) are minimized considerably," continued Dr. Bellicini.
The ciSNaP is the only non-powered negative pressure system designed to replace the current standard of care, which includes daily gauze and tape dressing changes, resulting in repeated exposure to air and germs. In addition to tension relief, Spiracur's NPWT device creates a vacuum-like suction over the wound, pulling the fluid from the wound to minimize the potential risk of infection. The small cartridge connects to a hydrocolloid-dressing bandage, providing a watertight protective layer, which allows a patient to shower and ensures that the peri-incision skin remains healthy.
"Following my left hip replacement surgery, I used the ciSNaP for one week and when I returned to Dr. Bellicini's office, my wound had healed completely with very minimal scarring," said Susan Mahoney, a cardiovascular technician in Greensburg. "I found the device to be extremely convenient in that there was no need to change dressings on a daily basis or worry about infection. Ten years ago I had my right hip replaced, however, the healing process and the resulting scar were much more significant compared to this surgery. I am extremely happy with the ciSNaP and the outcome of my surgery."
Debbie Redding, a real estate broker who is also from Greensburg, used the ciSNaP for her recovery from total hip replacement surgery this past January. "I had the new device on for one week, and at my check up with Dr. Bellicini, my sutures and wound healing looked more like it had been 10 weeks, not one week. It was unbelievable how nicely my wound healed. In fact, my recovery was so remarkable because of the ciSNaP, I was able to go back to work in just two weeks."
Spiracur's new device is commercially available in the United States. To date, over 100 new patients have been successfully treated with the ciSNaP following high-risk surgical procedures.
"Our investment in research and development will continue to produce innovative wound healing solutions such as the new ciSNaP System," said Gary Restani, president and chief executive officer of Spiracur Inc. "This device combines the proven clinical effectiveness of negative pressure therapy with an advanced controlled tension relief layer to help minimize infection and improve wound healing, offering an ideal solution for patients undergoing complex surgeries."
About Spiracur Inc.
Spiracur Inc., headquartered in Sunnyvale, Calif., is a privately held medical device company focused on the development of innovative wound healing technologies. Spiracur was founded out of the Stanford Biodesign Innovation Program in 2007. Its first product, the SNaP Wound Care System for the treatment of chronic and acute wounds, is the result of patient and clinician feedback that current negative pressure wound therapies were too cumbersome. The ciSNaP System expands Spiracur's product portfolio to include the surgical incision market. Both devices have been cleared by the U.S. Food & Drug Administration (FDA) and have received CE Mark approval. For more information, please visit http://www.spiracur.com.